Knut Hagen1,2, Lars Jacob Stovner3,4, John-Anker Zwart5,6. 1. Department of Neuromedicine and Movement Science, Faculty of medicine and health sciences, Norwegian University of Science and Technology, 7489, Trondheim, Norway. knut.hagen@ntnu.no. 2. Clinical Research Unit Central Norway, St. Olavs University Hospital, Trondheim, Norway. knut.hagen@ntnu.no. 3. Department of Neuromedicine and Movement Science, Faculty of medicine and health sciences, Norwegian University of Science and Technology, 7489, Trondheim, Norway. 4. Norwegian Advisory Unit on Headaches, St. Olavs University Hospital, Trondheim, Norway. 5. Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway. 6. Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND: Several previous studies have reported a cross-sectional association between elevated high sensitivity C-reactive protein (hs-CRP) and migraine. The aim of this population-based follow-up study was to investigate the influence of hs-CRP at baseline on the risk of developing migraine 11 years later. METHODS: Data from the Nord-Trøndelag Health Study performed in 2006-2008 (baseline) and 2017-2019 were used. A total of 19,574 participants without migraine at baseline were divided into three groups based on hs-CRP levels (< 3 mg/L, 3-9.99 mg/L and 10.00-20 mg/L). Poisson regression was used to evaluate the associations between hs-CRP levels and risk ratios (RRs) of migraine, and precision of the estimates was assessed by 95% confidence interval (CIs). RESULTS: In the multi-adjusted model, increased risk of migraine (RR 1.46, 95% CI 1.05-2.04) was found in the highest hs-CRP levels group compared to the lowest group. In the group with the highest hs-CRP levels, a nearly three times higher risk of chronic migraine (RR 2.81, 95% CI 1.12-7.06) was found, whereas no evident relationship was found between high hs-CRP level and risk of developing episodic migraine. CONCLUSIONS: The main finding in this 11-year follow-up was that hs-CRP levels between 10.00-20.00 mg/L at baseline was associated with increased risk of chronic migraine.
BACKGROUND: Several previous studies have reported a cross-sectional association between elevated high sensitivity C-reactive protein (hs-CRP) and migraine. The aim of this population-based follow-up study was to investigate the influence of hs-CRP at baseline on the risk of developing migraine 11 years later. METHODS: Data from the Nord-Trøndelag Health Study performed in 2006-2008 (baseline) and 2017-2019 were used. A total of 19,574 participants without migraine at baseline were divided into three groups based on hs-CRP levels (< 3 mg/L, 3-9.99 mg/L and 10.00-20 mg/L). Poisson regression was used to evaluate the associations between hs-CRP levels and risk ratios (RRs) of migraine, and precision of the estimates was assessed by 95% confidence interval (CIs). RESULTS: In the multi-adjusted model, increased risk of migraine (RR 1.46, 95% CI 1.05-2.04) was found in the highest hs-CRP levels group compared to the lowest group. In the group with the highest hs-CRP levels, a nearly three times higher risk of chronic migraine (RR 2.81, 95% CI 1.12-7.06) was found, whereas no evident relationship was found between high hs-CRP level and risk of developing episodic migraine. CONCLUSIONS: The main finding in this 11-year follow-up was that hs-CRP levels between 10.00-20.00 mg/L at baseline was associated with increased risk of chronic migraine.
Entities:
Keywords:
Epidemiology; Follow-up; General population; Inflammation; Migraine
Authors: Aster V E Harder; Lisanne S Vijfhuizen; Peter Henneman; Ko Willems van Dijk; Cornelia M van Duijn; Gisela M Terwindt; Arn M J M van den Maagdenberg Journal: J Headache Pain Date: 2021-11-24 Impact factor: 7.277